Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes

Area of Science:

• Microbiology
• Metabolic Diseases
• Human Physiology

Background:

• The gut microbiota plays a crucial role in host metabolism and disease.
• Type 2 Diabetes (T2D) involves complex factors like obesity and inflammation, influenced by gut microbes.
• Gut microbial imbalance (dysbiosis) is increasingly recognized as a risk factor for T2D.

Purpose of the Study:

• To review current findings on the gut microbiota's role in T2D.
• To explore causal links between microbiota and T2D using methods like fecal microbiota transplantation (FMT).
• To examine the impact of microbial metabolites and host genetics on T2D.

Main Methods:

• Literature review of associative and causal studies on gut microbiota and T2D.
• Analysis of studies utilizing fecal microbiota transplantation (FMT) and probiotic supplementation.
• Examination of microbial metabolites (e.g., SCFAs, TMAO) and their association with T2D.

Main Results:

• Dysbiosis is a significant risk factor for T2D.
• Microbial metabolites, including SCFAs and TMAO, are associated with T2D.
• Host genetics and epigenetics influence microbial composition, potentially explaining T2D heritability.

Conclusions:

• The gut microbiota is integral to T2D pathogenesis.
• Fecal microbiota transplantation (FMT), prebiotics, and probiotics show therapeutic potential for T2D.
• Understanding microbiota-host interactions is key for future T2D management strategies.